[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obstructive-hypertrophic-cardiomyopathy-ohcm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obstructive-hypertrophic-cardiomyopathy-ohcm":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,43,74,94,117,141,165],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100658060","evaluation-of-mavacamten-based-practice-in-chinese-adults-with-obstructive-hypertrophic-cardiomyopathy-100658060",false,"NCT07846059","Evaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy","Real-world Evaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy","REMAP-HCM","Inclusion Criteria:\n\nParticipants must meet all of the following criteria to be included:\n\n1. Diagnosis: Have a documented diagnosis of obstructive hypertrophic cardiomyopathy (oHCM), identified by the corresponding International Classification of Diseases (ICD)-10 codes in the medical record system.\n2. Medication Exposure: Have a first-ever recorded prescription for Mavacamten within the Patient Identification Period (24 October 2024 to 31 March 2026). This date is defined as the Index Date.\n3. Age: Be ≥ 18 years of age at the Index Date.\n4. Treatment Continuity: Have at least two valid clinical records of any type (e.g., outpatient visit, inpatient encounter, prescription refill, laboratory test, or echocardiogram) after the Index Date.\n\nExclusion Criteria:\n\nParticipants meeting any of the following criteria will be excluded:\n\n(1) Prior Use of Study Drug: Have any documented history of Mavacamten use (based on medical history records, prescription records, or clinical notes) at any time prior to the Index Date.","ALL","18 Years",{"count":20,"type":21},800,"ESTIMATED","OBSERVATIONAL","The study will describe how mavacamten is used in routine care for Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), including use as monotherapy or with other background\u002Fconcomitant oHCM medications.",[25],"Obstructive Hypertrophic Cardiomyopathy (oHCM)",[27,28,29],"Symptomatic obstructive hypertrophic cardiomyopathy (oHCM)","Mavacamten","Hypertrophic cardiomyopathy","NOT_YET_RECRUITING","2026-09-23",{"date":33,"type":34},"2026-09-29","ACTUAL",{"date":36,"type":21},"2026-09-30",{"date":38,"type":21},"2027-04-30",{"name":40,"class":41},"Bristol-Myers Squibb","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":42},"100655569","gradual-tapering-or-discontinuation-of-beta-blockers-after-stabilization-with-mavacamten-therapy-100655569","NCT07815301","Gradual Tapering or Discontinuation of Beta-Blockers After Stabilization With Mavacamten Therapy","Feasibility and Safety of Sequential Tapering and Discontinuation of Beta-blockers in Patients With Obstructive Hypertrophic Cardiomyopathy After Achieving Hemodynamic Targets With Mavacamten: a Multicenter, Randomized, Open-label, Parallel-group, Non-inferiority Trial (STEP-oHCM)","STEP-oHCM","Inclusion Criteria:\n\n1. Age 18 to 75 years.\n2. Diagnosis of obstructive hypertrophic cardiomyopathy (oHCM).\n3. Receiving mavacamten for ≥12 weeks at screening, with the current maintenance dose stable for ≥8 weeks; after completion of the 4-week run-in period, the total duration of mavacamten treatment at randomization should generally be ≥16 weeks.\n4. Receiving one and only one beta-blocker continuously for at least 4 weeks before randomization, with the beta-blocker type, dosing frequency, and daily dose remaining stable, and without concomitant use of a non-dihydropyridine calcium channel blocker.\n5. The last qualified echocardiographic assessment before randomization shows a resting left ventricular outflow tract (LVOT) peak gradient \\\u003C30 mmHg and a Valsalva-provoked LVOT peak gradient \\\u003C50 mmHg.\n6. Left ventricular ejection fraction (LVEF) ≥55% at randomization baseline.\n7. Clinically stable and considered by the investigator to be suitable for sequential tapering and discontinuation of beta-blocker therapy.\n\nExclusion Criteria:\n\n1. Previous LVEF \\\u003C50% during mavacamten treatment, or previous interruption or discontinuation of mavacamten because of reduced left ventricular systolic function.\n2. Heart failure decompensation requiring an emergency department visit, hospitalization, or intravenous treatment within 3 months before randomization; or, within 6 months before randomization, syncope not attributable to a clearly reversible cause, sustained ventricular tachycardia\u002Fventricular fibrillation, or other clinically significant unstable arrhythmia.\n3. Septal reduction therapy within 6 months before randomization, or anticipated need for surgical septal myectomy, alcohol septal ablation, or other septal reduction therapy during the 24-week study period.\n4. A definite indication for beta-blocker therapy other than oHCM for which the investigator considers dose reduction or discontinuation unsafe.\n5. An HCM phenocopy or another disease clearly responsible for left ventricular hypertrophy, including cardiac amyloidosis, Fabry disease, or other infiltrative, storage, or metabolic cardiomyopathies.\n6. Moderate-to-severe valvular heart disease, fixed left ventricular outflow tract obstruction, or another structural heart disease that may substantially affect LVOT gradients or assessment of the primary outcome.\n7. Severe renal impairment (estimated glomerular filtration rate \\[eGFR\\] \\\u003C30 mL\u002Fmin\u002F1.73 m²), end-stage renal disease, or ongoing dialysis.\n8. Severe hepatic impairment (Child-Pugh class C), decompensated liver disease, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3 times the upper limit of normal at screening, or other severe hepatic dysfunction considered by the investigator to potentially affect the safe use of mavacamten.\n9. Active malignancy, ongoing systemic anticancer therapy that may substantially interfere with study assessments, or an anticipated life expectancy \\\u003C1 year because of a serious comorbid condition.\n10. Pregnancy or breastfeeding, planned pregnancy during the study, or, for participants of childbearing potential, inability or unwillingness to use effective contraception.\n11. A drug interaction that cannot be adequately modified or avoided and may substantially affect mavacamten exposure, or anticipated need for continued use of a protocol-prohibited medication during the study.\n12. Other serious systemic disease, inability to complete the required follow-up or comply with the study protocol, or any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.","75 Years",{"count":53,"type":21},286,"INTERVENTIONAL",[56],"NA","This multicenter, randomized, open-label, parallel-group, non-inferiority trial will evaluate whether sequential tapering and discontinuation of beta-blockers is non-inferior to maintenance of the baseline stable beta-blocker dose in adult patients with obstructive hypertrophic cardiomyopathy (oHCM) who have achieved predefined clinical and hemodynamic stability during mavacamten treatment. Eligible participants will be randomly assigned in a 1:1 ratio to a sequential tapering and discontinuation group or a baseline stable-dose maintenance group. In the tapering group, the beta-blocker dose will be reduced stepwise approximately every 4 weeks, with complete discontinuation planned at Week 12 if predefined safety and stability criteria are met. Participants will be followed through Week 24. The primary objective is to compare the proportion of participants who maintain clinical and hemodynamic stability without protocol-defined treatment failure through Week 24. The feasibility and safety of complete beta-blocker discontinuation will also be evaluated.",[25],[60,28,61,62,63],"Obstructive Hypertrophic Cardiomyopathy","Beta-Blocker","Sequential Tapering and Discontinuation","Non-Inferiority Trial","2026-09-08",{"date":66,"type":34},"2026-09-11",{"date":68,"type":21},"2026-12",{"date":70,"type":21},"2028-12",{"name":72,"class":73},"First Affiliated Hospital of Wenzhou Medical University","OTHER",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":54,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":92,"locationsCount":4},"100655017","phase-4-efficacy-and-safety-of-an-lvef-guided-mavacamten-dose-up-titration-strategy-in-chinese-patients-with-symptomatic-obstructive-hypertrophic-cardiomyopathy-100655017","NCT07807384","Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy","Efficacy and Safety of a Left Ventricular Ejection Fraction-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Prospective, Multicenter, Open-Label Study","Inclusion Criteria:\n\n* 1\\. Adult patients diagnosed with obstructive hypertrophic cardiomyopathy (HCM) and classified as New York Heart Association (NYHA) functional class II-III. 2. Have received stable Mavacamten treatment for at least 12 weeks with a stable dose. 3. LVEF ≥ 55%.\n\nExclusion Criteria:\n\n* 1\\. Hypertrophy caused by other systemic diseases with a clear etiology. 2. Planned use of strong CYP2C19 inhibitors, moderate to strong CYP2C19 inducers, or CYP3A4 inducers during the study. 3. Planned use of disopyramide, ranolazine, verapamil combined with beta-blockers, or diltiazem combined with beta-blockers during the study. 4. Previous intolerance to Mavacamten. 5. Severe hepatic or renal dysfunction. 6. Pregnant or lactating women.",{"count":82,"type":21},115,[84],"PHASE4","This study aims to evaluate whether, under a treatment strategy primarily guided by left ventricular ejection fraction (LVEF), dose up-titration in adult patients with symptomatic obstructive hypertrophic cardiomyopathy who have received Mavacamten treatment for at least 12 weeks with a stable maintenance dose (as baseline) and with LVEF ≥55% can further reduce left ventricular outflow tract (LVOT) gradient after 24 weeks of treatment. It will also assess changes in hemodynamics, clinical symptoms, cardiac structure, and function. Furthermore, the study will conduct stratified analyses based on patients' baseline resting or Valsalva-provoked LVOT gradient levels at enrollment \\[\\\u003C30 mmHg vs. ≥30 mmHg\\] to explore differences in the aforementioned outcome measures among patients with different gradient levels, with the goal of providing evidence for individualized clinical dose adjustment.",[25],"2026-09-01",{"date":64,"type":34},{"date":90,"type":21},"2026-09",{"date":90,"type":21},{"name":93,"class":73},"Second Affiliated Hospital of Nanchang University",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":104,"conditions":105,"keywords":106,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":42},"100635808","mavacamten-outcomes-in-hypertrophic-cardiomyopathy-hcm-and-the-associated-patient-and-physician-experiences-in-the-us-100635808","NCT07557498","Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US","Mavacamten Real-World OutcomeS and the Associated PAtient and Physician ExpeRienCe With Hypertrophic CardioMyopathy in the United States (US) Community","SPARC-HCM","Inclusion Criteria:\n\nPhase I: retrospective chart review\n\nFor inclusion in the study, participants must meet ALL of the following criteria:\n\n* Are an adult aged 18 or over at baseline\n* Have a confirmed diagnosis of obstructive hypertrophic cardiomyopathy (HCM)\n* Have been prescribed mavacamten for obstructive HCM at one of the study sites between 28th April 2022 and 31st December 2024\n* Have not ever been enrolled in any interventional clinical trial involving any cardiac myosin inhibitor (enrollment in observational studies is permitted)\n* Are not enrolled in any interventional clinical trial at study baseline\n\nPhase II: patient survey • Participants must meet all inclusion criteria of Phase I: retrospective chart review and be able to read and understand English and have access to computer or smartphone to complete the survey\n\nExclusion Criteria:\n\n• None with the proviso that all inclusion criteria are met.",{"count":103,"type":21},362,"The purpose of this study is to understand the real-world clinical outcomes and treatment patterns of adults with obstructive hypertrophic cardiomyopathy (HCM) treated with mavacamten, and to understand patient and physician experiences with mavacamten treatment, in the US community-based practice",[25],[107],"Obstructive Hypertrophic cardiomyopathy (oHCM)","RECRUITING","2026-04-23",{"date":111,"type":34},"2026-04-29",{"date":113,"type":34},"2026-01-15",{"date":115,"type":21},"2027-06-17",{"name":40,"class":41},{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":54,"phases":126,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":140},"100621215","phase-2-ademetionine-in-obstructive-hypertrophic-cardiomyopathy-100621215","NCT07367724","Ademetionine in Obstructive Hypertrophic Cardiomyopathy","Safety and Efficacy of Ademetionine in Patients With Obstructive Hypertrophic Cardiomyopathy: A Multicenter, Double-Blind, Randomized Controlled, Phase 2 Study","Inclusion Criteria:\n\n* Meet the diagnostic criteria for HCM.\n* Age ≥ 18 years at screening.\n* LVEF ≥ 50% at screening.\n* Echocardiography demonstrates a resting or provoked LVOTG ≥ 30 mmHg at screening.\n* NYHA Functional Class II-III at screening.\n* Able to perform CPET.\n* Patients receiving treatment with β-blockers or non-dihydropyridine calcium channel blockers should have been on a stable dose for at least 6 weeks prior to randomization and are expected to maintain the same medication during the trial. Who have previously received cardiac myosin inhibitors (e.g., Mavacamten) must discontinue the treatment for at least 8 weeks prior to randomization.\n* Willing and able to sign the informed consent form and comply with all scheduled study visits.\n\nExclusion Criteria:\n\n* History of severe hypersensitivity to any component of Ademetionine 1,4-Butanedisulfonate Enteric-coated Tablets.\n* History of psychiatric disorders, or current use of antidepressants such as clomipramine.\n* Planned for any surgical (including septal reduction therapy) or interventional procedure during the trial period.\n* Planned use of cardiac myosin inhibitors (e.g., Mavacamten) during the trial period.\n* Currently pregnant or planning pregnancy.\n* Currently participation in another drug or device clinical trial.\n* History of any other disease with a life expectancy of less than 1 year.",{"count":125,"type":21},44,[127],"PHASE2","This study is a multicenter, double-blind, randomized controlled Phase 2 trial designed to evaluate the safety and efficacy of Ademetionine in patients with obstructive hypertrophic cardiomyopathy (oHCM). The study will recruit patients with oHCM who, under double-blind conditions, will be randomly assigned to either the Ademetionine group or the placebo group. Follow-up visits will be conducted every 4 weeks until 16 weeks from baseline. After 16 weeks, the study will evaluating the effect of Ademetionine on exercise capacity, heart failure symptoms, cardiac structure and function, and quality of life, as well as safety and tolerability of Ademetionine in this patient population.",[25],"2026-03-18",{"date":132,"type":34},"2026-03-20",{"date":134,"type":34},"2026-01-01",{"date":136,"type":21},"2027-12-31",{"name":138,"class":139},"China National Center for Cardiovascular Diseases","OTHER_GOV",3,{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":140},"100626770","biological-collection-for-the-purpose-of-exploring-genetic-and-clinical-biological-factors-associated-with-variability-in-response-to-mavacamten-in-the-treatment-of-obstructive-hypertrophic-cardiomyopathy-100626770","NCT07439952","Biological Collection for the Purpose of Exploring Genetic and Clinical-biological Factors Associated With Variability in Response to Mavacamten in the Treatment of Obstructive Hypertrophic Cardiomyopathy","MAVA PG","Inclusion Criteria:\n\n* \\- Patients aged ≥18 years\n* Diagnosis of obstructive hypertrophic cardiomyopathy (OHCM), based on the guidelines of the European Society of Cardiology (Arbelo et al. 2023), with unexplained left ventricular hypertrophy and a maximum LVOT gradient ≥ 50 mmHg at rest, or after Valsalva manoeuvre or exercise at the time of diagnosis, and an LVOT gradient with Valsalva manoeuvre ≥ 30 mmHg at selection\n* With cardiac symptoms defined as NYHA class II\u002FIII, persistent despite background treatment (beta-blockers or calcium channel blockers)\n* LVEF ≥55% at the start of treatment with mavacamten\n* Initiation of treatment with mavacamten or patient already receiving treatment\n* Prescription of pre-treatment CYP2C19 genotyping performed\n* Consent to participate signed by the patient\n* Beneficiary of health insurance\n\nExclusion Criteria:\n\n* Minors\n* Adults under guardianship (legal guardianship and curatorship) or judicial protection\n* Pregnant or breastfeeding women",{"count":149,"type":21},300,"The European Medicines Agency has required pre-treatment genotyping of CYP2C19 to determine the initial and maximum dosage, in order to avoid overexposure to mavacamten associated with a decrease in ventricular ejection fraction below 50% in slow metabolisers of CYP2C19 (AUC multiplied by 3.4). The study is a requalification for the search for DNA samples obtained during treatment in order to genotype the genes of interest.The primary objective of the study is to estimate, for each of the CYP2C19 phenotypes of interest determined by genotyping (ultra-rapid, rapid, normal\u002Fextensive and intermediate metabolisers), the proportion of patients who are non-responders to mavacamten at each time point (D0, Week 4, Week 8, Week 12 and Week 24 in the treatment of HCM). This is a multicentre (3 centres which are hospitals of APHP) study aiming to include 300 patients with obstructive hypertrophic cardiomyopathy treated with Mavacamten who underwent or are undergoing CYP2C19 genotyping at the start of treatment. The inclusion period is 36 months and the follow-up period is 6 months. The total duration of the study is 42 months.",[25],[153,154,155],"mavacamten","obstructive hypertrophic cardiomyopathy","polymorphisms of CYP2C19, CYP3A4\u002FCYP3A5 and CYP2C9","2026-02-26",{"date":158,"type":34},"2026-02-27",{"date":160,"type":21},"2026-02-05",{"date":162,"type":21},"2029-07",{"name":164,"class":73},"Assistance Publique - Hôpitaux de Paris",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":174,"conditions":175,"keywords":176,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":42},"100622392","mavacamten-post-marketing-surveillance-in-patients-with-obstructive-hypertrophic-cardiomyopathy-in-japan-100622392","NCT07383025","Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan","Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy (oHCM) in Japan","Inclusion Criteria:\n\n• All obstructive hypertrophic cardiomyopathy (oHCM) patients who initiate treatment with Mavacamten of the approved indications at medical institutions in Japan during enrollment period will be enrolled in this regulatory post-marketing surveillance (PMS) study\n\nExclusion Criteria:\n\n• Participants receiving Mavacamten for an off-label indication will be excluded from this PMS study",{"count":173,"type":21},200,"The purpose of this study is to assess the real-world effectiveness and safety of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) receiving mavacamten in Japan",[25],[177],"Obstructive hypertrophic cardiomyopathy (oHCM)","2026-01-26",{"date":180,"type":34},"2026-02-03",{"date":182,"type":34},"2025-05-21",{"date":184,"type":21},"2029-11-30",{"name":40,"class":41}]